Purpose of this Study
We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are diagnosed with UPS or a related poorly differentiated sarcoma</li>
<li>Have disease that is metastatic or unresectable</li></ul>
For more information about who can join this study, contact the study team at <a href= "mailto: marty.c.cauley@duke.edu">marty.c.cauley@duke.edu.</a>
<li>Are diagnosed with UPS or a related poorly differentiated sarcoma</li>
<li>Have disease that is metastatic or unresectable</li></ul>
For more information about who can join this study, contact the study team at <a href= "mailto: marty.c.cauley@duke.edu">marty.c.cauley@duke.edu.</a>
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 arms in the study:<ul>
<li>Arm A: If you are in this arm, you will take the study drug along with the standard drug (doxorubicin) used to treat this type of cancer.</li>
<li>Arm B: If you are in this arm, you will take the standard drug used to treat this type of cancer.</li></ul>
<li>Arm A: If you are in this arm, you will take the study drug along with the standard drug (doxorubicin) used to treat this type of cancer.</li>
<li>Arm B: If you are in this arm, you will take the standard drug used to treat this type of cancer.</li></ul>
Study Details
Full Title
EA7222: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Principal Investigator
Richard
Riedel
Protocol Number
PRO00116156
NCT ID
NCT06422806
Phase
III
Enrollment Status
Pending Open to Enrollment